MedTrace Logo

Stellate Ganglion Block for Major Depressive Disorder.

NCT04727229 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-02-09

No results posted yet for this study

Summary

This is a feasibility study, to investigate a new treatment option for major depressive disorders by performing a Stellate Ganglion Block (SGB). A SGB is an injection of local anesthetic into the sympathetic nervous system (peripheral nervous system) located in the lower part of the neck, to relieve pain in the head, neck, upper arm, and upper chest.

Conditions

Interventions

DRUG

Bupivacaine Hydrochloride

Injection of Bupivacaine near the stellate ganglion

DRUG

Normal Saline

Injection of Normal Saline near the stellate ganglion

Sponsors & Collaborators

  • Unity Health Toronto

    lead OTHER

Principal Investigators

  • Karim Ladha, MD · Unity Health Toronto

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-23
Primary Completion
2022-02-10
Completion
2022-03-10

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04727229 on ClinicalTrials.gov